bradykinin

Bradykinin (2-9) (Des-Arg1-bradykinin) is an amino-truncated peptide compound that is a metabolite of Bradykinin. It is formed by the cleavage action of Aminopeptidase P.

Bradykinin (1-7), an amino-truncated peptide derived from Bradykinin, is a metabolite formed through enzymatic cleavage by endopeptidase.

Bradykinin is an inflammatory mediator. It is a peptide that causes blood vessels to dilate (enlarge) via the release of prostacyclin, nitric oxide, and Endothelium-Derived Hyperpolarizing Factor. Bradykinin is a physiologically and pharmacologically active peptide of the kinin group of proteins, consisting of nine amino acids.

Bradykinin (1-5) is a major stable metabolite of Bradykinin, formed by the proteolytic action of angiotensin-converting enzyme (ACE). The Bradykinin (BK) fragment (1-5) (RPPGF) is one of the most stable naturally occurring metabolites and may be used as a marker for BK production in vivo.

Bradykinin (1-6) is an amino-truncated Bradykinin peptide and a stable metabolite of Bradykinin, cleaved by carboxypeptidase Y (CPY). This fragment of Bradykinin activates pain receptors and induces smooth muscle contraction.

Bradykinin (1-3) is a fragment of Bradykinin, which activates pain receptors.

Sar-[D-Phe8]-des-Arg9-Bradykinin acetate is a potent and selective bradykinin B1 receptor agonist (EC50 = 9.02 nM in rabbit aorta) that is resistant to aminopeptidase, kininase I and II (ACE) and neutral endopeptidase cleavage. Exhibits hypotensive and angiogenic activity in vivo.

Bradykinin potentiator-5 is a peptide inflammatory mediator, causes blood vessels to dilate (enlarge), and therefore causes blood pressure to fall.

Des-Arg9-[Leu8]-Bradykinin acetate is a potent antagonist of the bradykinin receptor 1 (B1R) used in renal fibrosis research [1].

Lys-(Des-Arg9,Leu8)-Bradykinin is a selective antagonist of the bradykinin B1 receptor [1].

[Des-Arg9]-Bradykinin acetate is a selective agonist of the Bradykinin B1 receptor.

Potent and selective bradykinin B1 receptor agonist (EC50 = 9.02 nM in rabbit aorta) that is resistant to aminopeptidase, kininase I and II (ACE) and neutral endopeptidase cleavage. Exhibits hypotensive and angiogenic activity in vivo.

Endogenous potent and highly selective bradykinin B1 receptor agonist (Ki values are 0.12 and > 30000 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. 16-fold more potent than [Des-Arg9]

Lys-[Des-Arg9]Bradykinin,TFA is Endogenous potent and highly selective bradykinin B1 receptor agonist (Ki values are 0.12 and > 30000 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. 16-fold more potent than [Des-Arg9]-Bradykinin.

Selective bradykinin B2 receptor agonist that is resistant to carboxypeptidase cleavage. 5-fold more potent and exhibits a more prolonged duration of action than bradykinin in vivo.

Endogenous bradykinin receptor agonist

Bradykinin (acetate) is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions. Enzymatically produced from kallidin in the blood, it is a powerful vasodilator that causes smooth muscle contraction, and may mediate inflammation. It has a role as a human blood serum metabolite and a vasodilator agent. It is a tautomer of a bradykinin(2+).

Lys-[Des-Arg9]Bradykinin acetate is an endogenous potent and highly selective bradykinin B1 receptor agonist (Ki values are 0.12 and > 30000 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. 16-fold more potent than [Des-Arg9]-Bradykinin.

Bradykinin antagonist.

(Hyp³)-Bradykinin acetate is an agonist of bradykinin B2 receptor and stimulates inositol phosphate production in cultured human fibroblasts.

[Des-Arg9]-Bradykinin ([Des-Arg9]-Bradykinin(2TFA))(2TFA) is an agonist of Bradykinin (B1) receptor.

Avoralstat (BCX4161) is an oral plasma kallikrein (PKK) inhibitor. Which is used for the treatment of hereditary angioedema.

Anatibant 2HCl is a small molecule bradykinin B2 receptor antagonist for the treatment of neurological disorders and may be used in the study of brain injury.

MK-0686 is an orally available bradykinin B1 receptor antagonist with potential anti-inflammatory activity.